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Cytochrome P450 (CYP) enzymes are important for drug metabolism. They chemically modify 
drugs to make them more soluble, which allows the drugs to be excreted from the body. Of the 
30 CYP enzymes, 6 (CYP1A2, 2C9, 2C19, 2D6, 2E1, 3A4/5) are of clinical interest because these 
enzymes are the key players in drug metabolism. Differences in genetics lead to individuals of 
the same species expressing different CYP enzymes. The different combination of CYP enzymes 
may affect the rate of drug metabolism or produce metabolites that may cause adverse side 
effects. Predicting drug metabolites and drug-drug interactions is important when designing 
and prescribing new drugs because other drugs can act as CYP activators or inhibitors. 
Duloxetine is an antidepressant mainly metabolized by CYP1A2 and CYP2D6 isotypes. In this 
experiment, Duloxetine was metabolized using rat microsomes, housing a variety of CYP 
isotypes. Efficiency of metabolism in the presence and absence of inhibitors was measured 
using HPLC-MS.
Abstract
For most drugs to be excreted from the body, they must first be inactivated and made more 
soluble.  Cytochrome P450 (abbreviated as “CYP”) isozymes are heme-containing membrane 
proteins that chemically modify drugs for metabolism, most commonly via oxidation.1 These 
proteins are found in the smooth endoplasmic reticulum of cells located in the liver, intestines, 
lungs, kidneys, plasma, and skin.  The main site of drug metabolism in the human body is the 
liver, therefore, P450 enzyme concentration and activity is highest in hepatic cells.3
CYP enzymes have been categorized using a common nomenclature system that includes the 
family name, subfamily, and the individual gene that encodes the enzyme. There are more than 
30 P450 enzymes that have been identified in human cells and belong to families 1-4. An 
estimated 90% of drug metabolism has been attributed to six P450 enzymes including CYP1A2, 
2C9, 2C19, 2D6, 2E1, 3A4/5 making these enzymes of greatest clinical interest.2
Drug metabolism varies from one person to the next. This is due to the wide variety of P450 
enzymes expressed in individuals. These differences in enzyme presence and effectiveness can 
cause different rates of drug metabolism from one individual to the next and can lead to 
adverse side effects. Some drugs can act as either CYP activators or inhibitors. CYP activators 
increase the rate of drug metabolism causing the drug to be excreted at a faster rate. This may 
cause the effects of the drug to be decreased or lost. Most CYP activators function by 
increasing expression of CYP enzymes. CYP inhibitors decrease the rate of drug metabolism. 
This can lead to a toxic buildup of the drug.4 Being able to predict and manipulate drug 
metabolites is useful when designing new drugs to decrease side effects, and can help predict 
drug-drug interactions when an individual is prescribed multiple drugs that share the same 
pathway. 
In this project, I analyzed the drug metabolites of a soluble antidepressant, duloxetine. 
Duloxetine is most commonly metabolized by CYP1A2 and CYP2D6, like many other 
antidepressants. Previous studies have shown a decrease in the production of duloxetine 
metabolites in the presence of both CYP1A2 and CYP2D6 isozyme specific CYP inhibitors.5
Therefore, these specific CYP enzymes are important for metabolism of duloxetine.
Metabolites were produced by incubating duloxetine with rat microsomes containing CYP 
enzymes of various isotypes. Metabolite production was monitored using HPLC-MS. The 
efficiency of drug metabolism was manipulated by adding a general cytochrome P450 inhibitor, 
SKF-525A. SKF-525A is a broad spectrum CYP inhibitor that inhibits CYP activity of all isotypes.6
Broad inhibition is expected to show an overall decrease in the percentage of metabolites 
produced and an increased concentration of duloxetine remaining in the sample. Data was 
collected using HPLC-MS. 
Introduction	
SmartCYP, a freely available online algorithm, was used to predict the metabolites of 
duloxetine. 
Results
Duloxetine can be metabolized in vitro when incubated with rat microsomes housing a variety 
of CYP enzymes, with or without an NADPH-generating system. To observe the effects of CYP 
inhibition on metabolite production a broad spectrum CYP inhibitor, SKF-525A, was be added to 
the incubation mixture. 
Rat microsomes, SKF-525A, NADP, G6P, and G6P dehydrogenase were purchased from Sigma-
Aldrich and Duloxetine was kindly provided by Dr. Myoung Lee. A 50 mM phosphate buffer (pH 
7.4) was used to make a stock solution of Duloxetine with a concentration of 1.6 mM and a 
stock solution of SKF-525A with a concentration of 1.85 mM. Using these stocks, incubation 
mixtures were prepared by adding 65 µl of either drug or drug + inhibitor, combined with 25 µl 
of rat microsomes, and 35 µl of additional buffer. Experimental controls included a sample 
containing only duloxetine and buffer and a sample with only SKF-525A and buffer.  Tubes were 
incubated for 2 hours. After incubation, 250 µl of methanol was added to stop the reaction. 
Tubes were centrifuged at top speed for 20 minutes and the supernatant from each tube was 
extracted and placed in a new tube. The tubes were stored in the freezer until they were run 
on the HPLC-MS. HPLC separates the components of a mixture and uses absorbance to identify 
them. Components of the mixture can be ionized and separated based on their mass to charge 
ratio by the mass spectrometer. A gradient of 5 mM ammonium acetate in water and 5 mM
ammonium acetate in acetonitrile and water (95:5) was used. The gradient started at 95% 
ammonium acetate in water and decreased to 5%. The run time was 35 minutes for each 
sample. The sample contained 50 µl of the incubation mixture diluted with 1 ml of ammonium 
acetate in water. The sample was run through the HPLC connected with the mass spectrometer 
and the type and percentage of each metabolite was determined using SIM and TIC filtered 
data. 
Materials	&	Methods Results	Continued	
Table 1: Percentage of unmetabolized duloxetine and of each metabolite produced was 
determined using the total ion chromatogram from the mass spectrometer. 
Discussion	
The peaks in the chromatogram were more spread out than expected, and the intensity of the 
peaks was very low. This may be due to duloxetine and its metabolites sticking to the C18 
column, or to product loss at some step in the procedure.  Future experiments would aim to 
get single, more pronounced peaks for each metabolite in the HPLC and mass spectrum data. 
This could possibly be achieved by modifying the gradient parameters on the HPLC, using one 
single solvent instead of a gradient, or injecting the sample directly into the mass 
spectrometer instead of using the HPLC-MS combined. 
By analyzing the total ion chromatogram, we find that duloxetine without the inhibitor showed 
100% metabolism. Metabolism was reduced by 10% in the presence of CYP inhibitor, SKF-525A. 
In both cases metabolism was high, most likely because there was a high concentration of rat 
microsomes added to both samples. Previous studies, completed by Dani Schmaus, diluted the 
microsomes with phosphate buffer. For this experiment, 25 µl of undiluted rat microsomes
were added to the incubation mixture, producing very high rates of metabolism. Another 
manipulation to the protocol was the removal of the NADPH-generating system. Previous 
research also showed the NADPH-generating system was not necessary to metabolize 
duloxetine. Removal of this system reduced the cost of the experiment, eliminated steps to 
create the NADPH-generating system from the procedure, as well as cleaned up the sample 
overall. An increase in CYP inhibition and metabolite production could be seen in future 
experiments if the concentration of SKF-525A was increased, rat microsome concentration was 
decreased, or isotype specific CYP inhibitors were used.
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Figure 2: According to this algorithm the most common metabolites of duloxetine by CYP 3A4 
should also be hydroxylated and N-demethylated products, but hydroxylation may occur at the 
nitrogen or amino carbon, rather than an aromatic carbon. This is predicted due to the 
different size of the CYP 3A4 and 2D6 active sites. 
Figure 3: Duloxetine is at the center with its metabolites including N-desmethyl duloxetine and 
4-hydroxy duloxetine on either side. Duloxetine with a methyl group removed creates N-
desmethyl duloxetine while addition of a hydroxyl group creates 4-hydroxy duloxetine. The 
molecular weights listed are after polarization of the molecule. 
Figure 4: Chromatogram of duloxetine after metabolism by CYP enzymes.
Figure 5: Chromatogram of duloxetine after metabolism by CYP enzymes in the presence of SKF-
525A, a general CYP inhibitor.
Figure 1: According to this algorithm the most common metabolites of duloxetine by CYP 2D6 
should be hydroxylated and N-demethylated products. We are not able to distinguish between 
hydroxylated products using the HPLC-MS.
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